Inj, erzofri, 1 mg
Products billed under this code include Erzofri.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Erzofri.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Erzofri | Luye Pharma USA Ltd | 72526-0105-11 | 39 | $607.893 |
| Erzofri | Luye Pharma USA Ltd | 72526-0106-11 | 78 | $1,215.786 |
| Erzofri | Luye Pharma USA Ltd | 72526-0107-11 | 117 | $1,823.679 |
| Erzofri | Luye Pharma USA Ltd | 72526-0108-11 | 156 | $2,431.572 |
| Erzofri | Luye Pharma USA Ltd | 72526-0109-11 | 234 | $3,647.358 |
| Erzofri | Luye Pharma USA Ltd | 72526-0110-11 | 351 | $5,471.037 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $15.587 | −$0.286 | 1 MG | Inj, erzofri, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $15.873 | +$1.382 | 1 MG | Inj, erzofri, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $14.491 | −$0.812 | 1 MG | Inj, erzofri, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $15.303 | −$1.461 | 1 MG | Inj, erzofri, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $16.764 | – | 1 MG | Inj, erzofri, 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.